Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis
Data from a retrospective natural history study of previously treated patients with advanced PDPGFRα D842V-driven GIST will be presented in a poster session at the 2018
The accepted abstracts are listed below and are now available online on the
2018
Presentation Title: A retrospective natural history study of patients (pts) with PDGFRα D842V mutant advances gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI)
Session Title: Sarcoma
Session Date & Time:
Abstract Number: 11533
Poster Board Number: 278
Location: Hall A,
23rd
Presentation Title: Avapritinib (BLU-285), a Selective KIT Inhibitor, is Associated with High Response Rate and Tolerable Safety Profile in Advanced Systemic Mastocytosis (AdvSM): Results of a Phase 1 Study
Session Title: Myeloproliferative neoplasms - Clinical
Session Date & Time:
Abstract Number: PF612
Location: Poster Area, Stockholmsmässan
About
Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other disease driven by the abnormal activation of kinases.
View original content with multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-data-presentations-at-upcoming-asco-and-eha-meetings-supporting-plans-for-rapid-development-of-avapritinib-in-patients-with-gastrointestinal-stromal-tumors-and-systemic-mastocytosis-300650273.html
SOURCE
Investor and Media Relations Contacts: Kristin Hodous, 617-714-6674, KHodous@blueprintmedicines.com; Jim Baker, 617-844-8236, JBaker@blueprintmedicines.com